BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3 [Yahoo! Finance]
BriaCell Therapeutics Corp. - Common Shares (BCTX)
Company Research
Source: Yahoo! Finance
Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer target for drugs both effecting cancer cells and blocking immune checkpoint activity BriaPro expects to advance anti-B7-H3 antibodies into development of proprietary antibody-drug conjugates, T cell engagers, and targeted immune checkpoint inhibitors with potential applications in multiple cancer indications BriaPro has filed US patent applications for this technology PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“ BriaCell ”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. (“ BriaPro ”), are pleased to announce that BriaPro is developing novel, high affinity antibodies to B7-H3, a key player in cancer progression, using molecular modeling techniques. BriaPro has file
Show less
Read more
Impact Snapshot
Event Time:
BCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCTX alerts
High impacting BriaCell Therapeutics Corp. - Common Shares news events
Weekly update
A roundup of the hottest topics
BCTX
News
- “Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine [Yahoo! Finance]Yahoo! Finance
- “Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature MedicineGlobeNewswire
- BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025GlobeNewswire
- BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data ReadoutGlobeNewswire
- BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025GlobeNewswire
BCTX
Sec Filings
- 12/23/25 - Form FWP
- 12/23/25 - Form S-1
- 12/11/25 - Form 10-Q
- BCTX's page on the SEC website